

1 **Heart-retina time analysis using electrocardiogram-coupled time-**
2 **resolved dynamic optical coherence tomography**

3

4 Philippe Valmaggia, ^{1,2,3,*} Julia Wolleb,¹ Florentin Bieder,¹ Hendrik P.N. Scholl,³

5 Philippe C. Cattin^{1,†} Peter M. Maloca ^{2,3,†}

6

7 ¹ Department of Biomedical Engineering, University of Basel, Hegenheimermattweg
8 167b/c, 4123 Allschwil, Switzerland

9 ² Institute of Molecular and Clinical Ophthalmology Basel (IOB), Mittlere Strasse 91,
10 4056 Basel, Switzerland

11 ³ Department of Ophthalmology, University Hospital Basel, Mittlere Strasse 91, 4031
12 Basel, Switzerland

13 * philippe.valmaggia@unibas.ch

14 † These authors contributed equally to this work.

15 **Corresponding author:** Philippe Valmaggia, Department of Biomedical
16 Engineering, University of Basel, 4123 Allschwil, Switzerland.

17 E-mail: philippe.valmaggia@unibas.ch

18 **Abstract**

19 The eye and the heart are two closely interlinked organs, and many diseases
20 affecting the cardiovascular system manifest in the eye. To contribute to the
21 understanding of blood flow propagation towards the retina, we developed a method
22 to acquire electrocardiogram (ECG) coupled time-resolved dynamic optical
23 coherence tomography (OCT) images. This method allows for continuous
24 synchronised monitoring of the cardiac cycle and retinal blood flow dynamics. The
25 dynamic OCT measurements were used to calculate time-resolved blood flow
26 profiles using fringe washout analysis. The relative fringe washout was computed to
27 generate the flow velocity profiles within arterioles at the optic nerve head rim. We
28 found that the blood column between the heart and the retina propagates within one
29 cardiac cycle, denoting the arrival time as the heart-retina time (HRT). In a group of
30 healthy subjects, the HRT was 144 ± 19 ms (mean \pm SD). The HRT could provide a
31 novel potential biomarker for cardiovascular health in direct relation to retinal
32 perfusion.

33 Introduction

34 The eye and the heart are closely connected ¹⁻³. The cardiovascular system plays a
35 crucial role in delivering blood to the eye. The blood travels through a sequence of
36 arteries, including the carotid, ophthalmic, and central retinal arteries, until it reaches
37 the retina. The fine bed of capillary structures guarantees the delivery of nutrients at
38 the retina, which is essential for maintaining the visual function. Perturbances of
39 blood flow towards the eye can cause ischemic occlusions or haemorrhages,
40 ultimately leading to vision loss ⁴⁻⁷. The heart's function can be analysed with the
41 electrocardiogram (ECG), precisely measuring the cardiac rhythm and anomalies ⁸.
42 Analysing the cardiac cycle enables us to detect the moment of contraction of the
43 ventricles, which leads to the blood being pumped towards the corporal circulation.
44 The eye, specifically the retina, can be imaged with optical coherence tomography
45 (OCT) ⁹. OCT allows for a non-invasive assessment of ocular structures and
46 generates high-resolution images on a micrometre scale ¹⁰. Recent developments in
47 OCT have enabled us to measure OCT dynamically, even with devices approved for
48 routine clinical use ¹¹. These dynamic OCT acquisitions allow the estimation of
49 dynamic flow profiles within vessels of the retinal vasculature and were suggested to
50 represent a propagation of the cardiac cycle pulsation ¹¹. These time-resolved
51 dynamic blood flow profiles surpass certain limitations of optical coherence
52 tomography angiography (OCTA) providing qualitative perfusion maps, variable
53 inter-scan time analysis (VISTA) providing quantitative single-velocity (per vessel)
54 perfusion maps, or laser speckle flowgraphy (LSFG) providing en-face flow profiles
55 ¹²⁻¹⁴. The time-resolved dynamic OCT acquisitions allow a depth-resolved flow
56 profile analysis with a temporal resolution as fast as 101 Hz per B-scan for an
57 acquisition with 125 kHz per A-scan on B-scans with 1024 A-scans.

58

59 However, the propagation of the cardiac pulse wave is poorly understood because
60 the cardiac and retinal acquisitions are not synchronised. Coupling devices could
61 provide additional information about potential mismatches between the cardiac cycle
62 pulse waves and the pulse waves recorded at the retinal level. To this end, we
63 investigated the feasibility of linked acquisitions by coupling an ECG to a time-
64 resolved OCT device. The importance of timestamp matching must be emphasised
65 here, which is why it was decided to acquire the ECG information with an open-
66 source device capable of recording the ECG signal with microsecond precision. The
67 time-resolved OCT images have integrated timestamps, which we can use to match
68 the two time series. Both clocks were synchronised using a network time protocol
69 (NTP) server.

70

71 We aimed to generate a new option to analyse information regarding the propagation
72 of cardiac pulsations towards the eye by linking the information of the ECG to the
73 time-resolved OCT. Knowledge about the propagation velocity of the cardiac pulse
74 wave could be helpful in finding potential turbulences in the pathway and give a
75 general overview of cardiovascular health, and specifically, risks for cardiovascular
76 disturbances manifesting in the retina. We introduce the heart-retina time (HRT),
77 which represents the time the blood column needs to propagate from the heart to the
78 eye. We further aim to present with this work the feasibility of ECG-coupled time-
79 resolved OCT acquisitions, the correlation between the cardiac cycle and retinal
80 pulse waves and the potential of the HRT as a biomarker.

81

82 **Methods**

83 **Study design and patient population**

84 This was a cross-sectional observational cohort study in healthy subjects. The
85 inclusion criteria contained an age of at least 18 years and no history of vascular
86 diseases or ophthalmic surgery. Further, the participants did not smoke or drink
87 coffee six hours before the measurements to prevent possible effects on the retinal
88 microvasculature ¹⁵. Each subject was informed about the study and written informed
89 consent was obtained. The study was approved by the Ethics Committee
90 Northwestern and Central Switzerland (EKNZ_2021-02360) and performed in
91 accordance with the declaration of Helsinki.


92

93 **Hardware description**

94 The OCT device used for this study was a Spectralis (Heidelberg Engineering
95 GmbH, Heidelberg, Germany). The device allowed for a modification of the scan
96 patterns and the integration time with an investigational acquisition module ^{16,17}. The
97 ECG device used for this study was the open-source vitals monitor Healthy Pi v4.4
98 with a 3-lead ECG (Protocentral, Bangalore, India). The Healthy Pi v4.4, based on
99 an ESP32 microprocessor, had the capability to record ECGs with a temporal
100 frequency of 125 Hz ¹⁸. The Arduino code was modified to include timestamps with a
101 microsecond precision into the same data packet as the ECG samples ¹⁹. Power
102 supply and data transfer were done with a high-speed micro-USB 2.0 cable and
103 connected to the same computer as the Spectralis. The programming of the ECG
104 was performed with the Arduino language in IDE V 1.8.13 and a graphical user
105 interface was generated with Processing V 3.5.4.

106 The timestamps of the OCT device were generated via the computer clocks whereas
107 the timestamps for the ECG acquisitions were generated via the ESP32
108 microprocessor clock. The clocks were synchronised to the NTP server
109 ntp11.metas.ch of the Swiss Federal Office of Metrology and Accreditation ²⁰. The
110 ESP32 microprocessor was synchronised via WIFI and the synchronisation of the
111 OCT timestamps was performed via a LAN cable connection. A schematic overview
112 of the acquisition setup can be found in Figure 1.

113



114

115 **Fig. 1.** Electrocardiogram-coupled optical coherence tomography.

116 Time-resolved dynamic OCT and ECG data are recorded from a subject synchronously. The data is transferred
117 to a central computer. The timestamps of the ECG and the OCT are synchronised via a Network Time Protocol
118 (NTP) server. The OCT timestamps are synchronised via a direct connection to a stratum 1 NTP server. The
119 timestamps of the ECG are synchronised with the same NTP server via timestamp synchronisation request via
120 WIFI.

121 **Data acquisition**

122 The demographic characteristics of the study subjects (age, sex, height) were
123 obtained from the study subjects before the measurements. An example OCT
124 volume was acquired to familiarise the study subjects with the OCT device and the
125 specific fixation target. Following this initial test, the patients were connected to the
126 ECG device and seated in front of the OCT. Timestamp synchronisation was
127 performed and tested before the acquisitions started.

128

129 Three-lead ECG acquisitions were started, and data were continuously recorded to a
130 .csv file, including the timestamps with a microseconds precision and the ECG
131 voltage in arbitrary units generated by the HealthyPi (HP value). The OCT
132 acquisition module was then initiated, and the patient asked to remain calm and
133 fixate on the blue cross target provided by the manufacturer. An equal illumination of
134 the scanning laser ophthalmoscopy (SLO) in all image areas was verified and the
135 acquisition location of the B-Scan was steered to the desired position. Continuous B-
136 scans were then acquired at the superior and inferior optic nerve head rims of both
137 eyes. The nominal acquisition line-scan rate was set to 20 or 85 kHz, corresponding
138 to an integration time of 44.8 or 11.2 μ s, respectively. The B-scans were
139 continuously acquired for approximately 7 seconds with a scan pattern of 1024 \times 496
140 pixels on a field-of-view (FOV) of 10°. In case of blinks or bad signal quality, the
141 recorded data were not used for further analysis.

142 Data processing

143 The ECG data were resampled to fixed interval timestamps at the 125 Hz acquisition
144 rate with linear interpolation for missing ECG values. Following this, the R-Peaks of
145 the ECG were extracted using the “EngZee” algorithm with an implementation in
146 Python ^{21,22}. The binary R-Peak signals were then smoothed using a Gaussian filter
147 ($\sigma = 1.25$) and the values afterwards normalised between 0 and 1. The heart rate
148 was then given by the R-Peaks.

149

150 The OCT data were exported in RAW format (.vol). Each of the B-scans was
151 matched with a timestamp with milliseconds precision. The timestamps were
152 exported with the corresponding image included in the .vol file header. Pixel
153 intensities in the .vol format are stored in normalised values between 0 and 1. For
154 visualisation purposes, these pixel intensities were transformed for each as $V(x,y) =$
155 $255 \times \sqrt[4]{I(x,y)}$, where $V(x,y)$ denotes the pixel intensity for visualisation at
156 coordinates (x,y) and $I(x,y)$ denotes the normalised original intensity.

157

158 As a first step after intensity transformation, the B-scans were registered with a rigid
159 transformation using a pyramid processing framework ²³. The framework was
160 modified and an average of the first ten images of each time series image stack was
161 taken as reference image for the registration of the B-scans on each other. The
162 annotation of the vessel centres was then manually performed. For this, the
163 registered volumes were loaded as 3D image stacks into 3D Slicer V4.11. The
164 arterial centres were manually annotated as landmarks in each single B-Scan. The
165 vessel centres were identified by 1) identifying the horizontal centres point by

166 identifying the shadow behind the vessel, and 2) Identifying the anterior-posterior
167 centres by identifying the centre between the hyperreflective vessel walls ²⁴.

168

169 Subareas surrounding the arteriole centres of 7×7 pixels (corresponding to ~20×27
170 μm) were then extracted along the time series. Inside these subareas, the signal-to-
171 noise ratio SNR was calculated by dividing the average signal intensity of the
172 subarea divided by the noise level of the B-scan. Assuming shot-noise limited
173 detection, the B-scan noise level was approximated by dividing the maximum
174 intensity extracted from the raw data by the Heidelberg Quality score. The SNR for
175 the subarea of each B-Scan was calculated as:

176

$$\text{SNR}_{\text{Subarea}_i} = \frac{1}{W_i \times H_i} \times \left(\sum_{x=1}^{W_i} \sum_{y=1}^{H_i} I_i(x, y) \right) \times \frac{1}{\frac{\max(I_i)}{Q_i} \times 10^{10}}, \quad (1)$$

177

179 where i denotes the index of the B-scan, $I(x, y)$ denotes the intensity at the coordinates
180 (x, y) . The width and height of the subarea are denoted as w and h . $\max_i I_i$ denotes the
181 maximum intensity obtained from the metadata of the B-scan, and Q denotes the
182 Heidelberg Quality score in decibel (dB). Each i -th B-scan was matched to a
183 timestamp with ms precision, which was also stored in the metadata.

184 The SNR of each subarea was then compared with a reference SNR to calculate the
185 drop in SNR (SNR_{Drop}). As reference level, the peak SNR on a pixel level was
186 chosen. The SNR_{Drop} was used to calculate relative flow velocity profiles according to
187 ^{11,25}.

188

$$\text{SNR}_{\text{Drop}} = \frac{\sin(k_0 \Delta z)^2}{(k_0 \Delta z)^2}, \quad (2)$$

191

192 where $k_0 = 2 * \pi / \lambda$ and $\Delta z = n * v * \tau$. The equation was solved numerically for v , the
193 velocity of the axial component of the motion. In these equations, k_0 denotes the
194 central wavenumber, λ is the central wavelength of the light source, Δz corresponds
195 to the displacement in the z-axis, n is the eye's refractive index, and τ denotes the
196 integration time. Multiple possible solutions exist, and every numerical solution
197 calculated for each B-scan was stored as a potential flow velocity.

198

199 The pulse wave analyses for the correlation with the cardiac cycle were performed
200 with the envelope function of the maximal numerical solution of Eq. (2). Local
201 maxima of the first derivative of the flow profile were taken to identify the sharpest
202 rises of the blood flow velocity, representing the arrival time of the pulse propagation
203 at the retina. The local maxima were identified within the time series bins correlating
204 to the heart rate, which was identified by the ECG. These local maxima were then
205 processed in the same way as the R-Peaks: They were binarised along the time axis
206 as single time points, and the Gaussian filter ($\sigma = 1.25$) was applied, followed by a
207 $[0, 1]$ normalisation.

208

209 The timelines of the ECG R-Peaks and the pulse arrival times of the time-resolved
210 OCT data were then compared with cross-correlations. This was used to calculate
211 the lag between the two time series, where the OCT time series served as the
212 baseline for the cross-correlation. The ECG data was extracted from 10 seconds
213 prior to the first B-scan of the time-resolved OCT data until 1 second after the last B-
214 scan. The lag values were then sorted according to the argmax of the cross-
215 correlation values to identify the most probable offset between the moment of the
216 contraction of the heart ventricles (ECG R-Peaks) and the arrival at the retina
217 (sharpest rise in OCT blood flow velocity profile).

218

219 The HRT was then denominated for the time needed for the arrival at the retina. This
220 time corresponds to the time the impulse to the blood column needs to arrive from
221 the contraction of the left cardiac ventricle, as identified by the R-Peak at the retina.
222 This pulse propagation times aim to reveal information about the rigidity of the
223 vessels. Hence, information about the functioning of the cardiovascular system can
224 be obtained by combining recordings of the electrical heart activity with an ECG and
225 imaging of the retina with structural OCT.

226

227 The timestamp synchronisation of the OCT and the ECG was performed via
228 timestamp synchronisation with the NTP server, including an offset correction for
229 asymmetric network synchronisation between both devices. Several
230 synchronisations have been completed within the same network to assess the
231 reliability. The programming tasks for image analysis were carried out using Linux
232 shell scripts, Python 3.9 (Python Software Foundation, Wilmington, USA), and R

233 V4.2.2 (developed by the Foundation for Statistical Computing, Vienna, Austria). For
234 data visualisation, Python 3.9, R V4.2.2, and 3DSlicer V4.11 were used ²⁶.

235

236 **Statistical analysis**

237 The statistical analysis focused on different aspects of the data. First, we analysed
238 the flow velocity profiles, including the acquisition characteristics, the calculated
239 velocities and the SNR. The correlation with the ECG data was then analysed
240 qualitatively by plotting the time series and quantitatively with cross-correlations. The
241 reproducibility of the HRT was assessed for intra-subject, inter-subject, intra-exam,
242 and intra-vessel variability. These variabilities were analysed with the coefficient of
243 variation (CoV). Descriptive values in this manuscript are presented as mean \pm
244 standard deviation (SD) or median [interquartile-range (IQR)].

245

246 **Results**

247 **Feasibility of coupled ECG and time-resolved OCT acquisitions**

248 The synchronous ECG and OCT data acquisition, including timestamp
249 synchronisation, was feasible and well-tolerated in all subjects. Two subjects were
250 female, and three were male. The subjects were 24 to 32 years old and healthy. In
251 total, 90 arterioles were analysed in 70 acquisitions at the optic nerve head. In right
252 eye acquisitions (n=47), 25 arterioles have been analysed at the superior part of the
253 optic nerve head and 22 at the inferior part. In left eye acquisitions, 23 arterioles have
254 been analysed at the superior part and 20 at the inferior part. 54 arterioles from 39
255 acquisitions have been acquired at a nominal A-scan rate of 20 kHz, and 36 arterioles
256 from 31 acquisitions have been acquired at a nominal A-scan rate of 85 kHz. From
257 these acquisitions, a total of 26'100 arteriole centres have been manually annotated
258 in all B-scans combined. Further information about the acquisition parameters can be
259 found in Table 1, including an overview of the calculated velocity flow profiles.

260

261 The matching of the OCT and the ECG device is visualised in Figure 2 as a
262 screenshot. The corresponding recording can be found in Supplementary Video 1. It
263 shows the processed data, including the registered time-resolved OCT B-scans, the
264 corresponding ECG trace and the acquisition position of the B-scan on the SLO image.
265 The B-scan size in pixels, the FOV and the conversion to real size were extracted from
266 the metadata of the .vol files. The ECG data is presented with the time elapsed since
267 the last R-Peak as well as the percentage of the current cardiac cycle completed.
268 Minor eye movements during the acquisition occurred. The registration process can
269 compensate for motion in the anterior-posterior and fast-scanning directions. This can
270 be identified through the black boxes at the border of the images. However,

271 movements that were non-collinear with the fast-scanning direction could not be
 272 compensated as eye tracking was disabled.

273

274


275

Table 1. Acquisition overview per nominal A-scan rate

	20 kHz, n = 54	85 kHz, n = 36
Exam Duration [ms]	7144 (6908, 7480)	6879 (6879, 6880)
Annotated B-scans per Image Stack [n]	145 (140, 152)	512 (512, 512)
SNR_{B-scan} [dB]	42.0 (40.2, 44.1)	36.1 (34.4, 37.7)
Peak B-scan Intensity [RAW value × 10⁶]	1037.4 (756.1, 1470.4)	954.2 (737.7, 1610.7)
Vessel Intensity [RAW value × 10⁶]	7.9 (2.4, 61.8)	49.6 (19.9, 129.3)
SNR_{Vessel} / Peak SNR_{Vessel} [%]	2.1 (1.5, 3.3)	2.5 (1.7, 3.2)
Average Velocity [a.u.]	14 (10, 17)	48 (41, 58)
Minimal Velocity [a.u.]	5.8 (5.6, 5.9)	24.1 (23.6, 24.5)
Maximal Velocity [a.u.]	22 (15, 29)	73 (59, 92)

Results are presented as median (IQR) of the average values per image stack

n: number of time-resolved image stacks; SNR: signal-to-noise ratio; SNR_{B-scan}: SNR in the complete B-scan; SNR_{Vessel}: Average SNR in the vessel subareas of the B-Scan; Peak SNR_{Vessel}: maximum SNR on a pixel level in the complete vessel subarea, corresponding to the reference SNR for velocity calculations; RAW value: value extracted from the raw .vol OCT files; a.u.: arbitrary unit; IQR: interquartile range.




276
277 **Fig. 2.** Overview of an ECG-coupled dynamic time-resolved OCT acquisition.

278 The upper half of the image shows the B-scan that corresponds to the specific moment in the cardiac cycle. The
279 cardiac cycle is indicated in the bottom left, where the red vertical line indicates the current moment. The red
280 arrow in the image on the bottom right shows the acquisition location of the B-scan. FOV: field of view. SLO:
281 Scanning laser ophthalmoscopy, ECG: electrocardiogram, HP value: Healthy Pi ECG voltage values.

282 **Correlation between the cardiac cycle and retinal pulse waves**

283 Supplementary Video 1 shows the clear pulsatile intensity changes at the centre of the
284 arterioles at the inferior part of the optic nerve head. These pulsatile intensity changes
285 due to fringe washout reflect changes in the flow speed within the retinal vessels¹¹.
286 The pulsations in the calculated blood flow profiles corresponded in frequency to
287 the heart rate. The envelope function of the maximal calculated flow velocity allowed
288 to identify the local sharpest rises of the pulse wave. The sharpest rises of the pulse
289 wave were used to determine the arrival of the pulse wave at the retina. The plotting
290 of the sharpest rise and the R-Peaks revealed that both peaks occurred with relative
291 constant lags.



292
293

Fig. 3. Peak signal extraction from OCT and ECG data.

294 The time since OCT acquisition start on the x-axis is the same for all subfigures. The first plot shows the average
295 signal-to-noise ratio (SNR) in the extracted subareas ($\mu 7 \times 7$ pixels) over time. The second plot shows the
296 calculated axial flow velocity values based on fringe washout, where the NSI represents the numerical solution
297 index. The third plot shows the velocity gradient of the envelope function of the second subplot, where the
298 sharpest rise is automatically detected. The fourth plot shows the ECG signal from the HealthyPi (HP) with
299 detected R-Peaks. The detected peaks from both ECG and OCT are then plotted on top of each other in the fifth
300 plot.


301 The example OCT subarea SNR, the calculated axial flow velocity profiles, the
302 velocity gradients with the sharpest rise, and the ECG trace with the R-Peaks are
303 visualised in Figure 3 for the right artery (A1) of the Supplementary Video 1.
304 Supplementary Video 2 show another example of ECG-coupled OCT at the optic
305 nerve head. The ocular blood flow pulsations match in frequency with the heart beat.

306

307 The calculated axial flow profiles are represented as a scatter plot, where each B-
308 scan is represented as a pillar of scatters on the x-axis. Each numerical solution to
309 the SNR_{Drop} equation is represented as a scatter, where the index of the numerical
310 solution is indicated in the colormap. The velocity gradient is calculated for the
311 envelope function of the maximal calculated flow velocity. The sharpest rises are
312 hence depicted as the local maxima of the first derivative of this envelope function.
313 The “EngZee” algorithm provided reliable detection of the R-Peaks in the ECG trace.

314

315 The timepoints of these signals were encoded as binary information with Gaussian
316 smoothing to allow for uncertainty in the signal detection. The cross-correlation of both
317 signals enabled to determine the most probable delay for the HRT. The ECG data was
318 padded 10 seconds before the start and 1 second after the end of the OCT signal. The
319 normalised cross-correlation of both signals showed the expected intermittent spikes
320 where the argmax of the signal corresponded to the most probable peak. Figure 4
321 visualises the normalised cross-correlation of both signals, showing the most probable
322 offset of the ECG to the OCT at -136 ms, which corresponds to a HRT of 136 ms.
323 These findings showed that the R-Peaks and the sharpest rises of the pulse waves
324 correlated well.



325

326 **Fig. 4.** Signal analysis for the determination of the heart-retina time (HRT).

327 The top row shows the R-Peaks from the ECG signal, the middle row shows the times of the sharpest rise in the

328 OCT flow velocity signal and the bottom row shows the normalised cross-correlation of both signals. The ECG

329 signal has been extended for 10s before the start and 1s after the end of the OCT signal. The highest peak in the

330 normalised cross-correlation represents the most probable offset of the ECG towards the OCT signal,

331 representing the additive inverse of the HRT.

332

333 **The heart-retina time as a potential biomarker**


334 The first step to calculate the HRT was to find out how many pulse waves are on the

335 way from the heart to the eye. As seen in Figure 4, the cross-correlation signals are

336 repetitive peaks that occur due to the pulsatile nature of the velocity peaks. The

337 argmax of this function provided the most probable offset for each of the 90 annotated


338 vessels. Figure 5a shows a clearly distinguishable mode of the cross-correlation
339 histogram at the bin of -150 to -100 ms. This indicates that the blood column between
340 the heart and the retina is propagated within one heart cycle.



341
342 **Fig. 5.** Heart-retina time (HRT) results overview. **a** Histogram plot with a bin width of 50ms for the argmax of the
343 cross-correlation signals showing that the most probable delay between the R-Peak and the arrival of the pulse is
344 within one cardiac cycle. **b** HRTs of the five included subjects showing good intrasubject and inter-subject
345 reproducibility. **c-f** HRTs of different acquisitions within the same vessels.

346 The HRT was then calculated for each of the acquisition time series with the argmax
347 of the cross-correlation signal within one heartbeat, the results further apart being
348 identified as outliers. The HRT is shown as the additive inverse of the calculated offset.
349 The HRT showed good intersubject and intrasubject reproducibility. The HRT of all
350 acquisitions was 144 ± 19 ms (mean \pm SD). A visualisation of the measurements for
351 each subject can be found in Figure 4b. The intersubject CoV was 0.09, and the
352 intrasubject CoV was 0.11 ± 0.03 .

353 Figure 5c-f shows the results of several acquisitions where more than one vessel was
354 annotated. Each subplot represents one acquisition location and each Exam ID
355 represents one time series. The intra-exam CoV in case more than one vessel was
356 annotated was 0.07 ± 0.04 . The intra-vessel CoV in case the HRT was calculated in
357 more than one exam was 0.09 ± 0.05 . Supplementary Video 3 shows a representation
358 of an acquisition where three arterioles were annotated and evaluated to calculate the
359 HRT. The video visually shows the synchronous arrival of the pulse waves in all three
360 annotated arterioles. In Figure 6, the available information from an ECG-coupled time-
361 resolved dynamic OCT with three annotated arterioles is shown.



362
363

364 **Fig. 6.** Overview of the information available in ECG-coupled dynamic time-resolved OCT, showing an acquisition
365 with blood flow profiles from three annotated arterioles (A1, A2, A3). The identification of the arterioles in the OCT
366 was made on the corresponding SLO image. The blood flow profiles show synchronous pulsatility, corresponding
367 in frequency with the cardiac cycle over the synchronous acquisition of 7 seconds. The analysis of the delay allows
368 to calculate the HRT for all of the annotated vessels

369 Discussion

370 In this study, we developed a method to link the cardiac cycle to the blood flow
371 pulsations in the retina. We connected a commercially available OCT device to an
372 open-source ECG and merged the acquisitions via synchronised timestamps.
373 Pulsatility was found in the OCT flow velocity profiles, and the sharpest rises of the
374 pulse waves were identified. These peaks were cross-correlated with the R-Peaks
375 from the ECG. We found that the blood column between the heart and the retina
376 propagates within one cardiac cycle. Via an analysis of the lag between the two
377 signals, we can calculate the HRT. We propose this HRT as a potential new biomarker
378 for the analysis of cardiovascular health.

379

380 Cardiovascular diseases, including hypertension, frequently manifest in both the heart
381 and the eye¹. Conditions like hypertensive retinopathy, which can result in vision loss,
382 are examples of this interconnectedness²⁷. Many ideas have been developed to
383 identify systemic diseases from the eye by gaining information about the vascular state
384^{28,29}. Few studies have been conducted to link the heart and the eye via ECG to assess
385 the pulsatile vessel calibre on fundus photographs or with ultrasound to assess the
386 larger carotid or ophthalmic arteries in synchronicity with the heart³⁰⁻³³. To the best of
387 our knowledge, we present the first link of an ECG with OCT to assess retinal blood
388 flow profiles.

389

390 With this method, we showed that the blood flow propagates towards the retina within
391 one cardiac cycle. This finding might be counterintuitive initially as the arm-retina time
392 from fundus fluorescein angiography (FFA) is in the range of 7-15 seconds³⁴. In FFA,
393 a dye bolus is injected into the arm of the patient and then propagated towards the

394 peripheral circulation. The fluorescein is mainly bound to human serum proteins after
395 injection^{35,36}. For the FFA arrival time, the dye hence travels at the same speed as
396 the particles in the blood. In our study using ECG-coupled OCT analysis, we observed
397 significantly shorter delay times for the HRT. This result can be described similarly to
398 a hose filled with water: when the water pump is activated, water begins to flow out of
399 the hose almost instantly, rather than requiring the water to traverse the entire length
400 of the hose. When the pump is restarted, water starts almost immediately to flow out
401 of the hose opening, without the water having to travel all the way through the hose.
402 Hence, we hypothesise that we rather measure the propagation of the blood column
403 instead of the propagation speed of single blood particles.

404

405 The assessment of blood flow in conjunction with the heart has been explored in
406 several other fields, with a particular focus on the pulse transit time³⁷⁻³⁹. The pulse
407 transit time measures the time taken for blood to travel between two locations in the
408 body. The transit time for the blood to travel from the heart, as measured from the R-
409 Peak in the ECG, to the carotid artery has been measured at 100 ± 11 ms³². The
410 pulse transit times for the blood to arrive from the heart to the ear, finger, and toe have
411 been measured at 126, 269, and 266 ms, respectively⁴⁰. The measured HRT of 144
412 ± 19 ms is well compatible with these previous findings.

413

414 Pulse transit times, in general, have been shown to correlate well with blood pressure
415 and have often been suggested as an additional biomarker, extending or even
416 substituting cuff-based blood pressure measurements^{38,39,41}. The pulse wave velocity
417 can be calculated by dividing the distance between the two measurements by the
418 pulse transit time⁴². Shorter pulse transit times hence correspond to faster pulse wave

419 velocities, and faster pulse wave velocities are found in stiffer arteries⁴³. The analysis
420 of pulse wave velocity can not only be used to estimate the blood pressure but also to
421 assess target organ damage⁴⁴. Faster pulse wave velocities have been found to be
422 associated with the risk of stroke and to be predictive of cerebrovascular events⁴⁵. As
423 the retina shares a significant proportion of the perfusing vessels with the rest of the
424 brain, the HRT has the potential to lead to a better understanding of the pulse wave
425 propagation towards arterioles perfusing the central nervous system.

426

427 With the proposed HRT, we aim to contribute to the field of pulse arrival times. The
428 HRT in this first feasibility study showed good intra-subject, inter-subject, intra-exam
429 and intra-vessel reproducibility. The intra-subject, inter-subject and intra-vessel
430 variabilities were in a very similar range. We estimate these variations to be
431 attributable to noise and natural variability, which could be similar to the heart-rate
432 variability. The heart-rate variability can be used for an objective assessment of stress
433⁴⁶. The intra-exam CoV showed the lowest variability, however, it was still existent.
434 This variability between different vessels in the same examination comes through
435 different pulse wave forms in the OCT flow profiles, as the identified R-Peaks are the
436 same for all within the same examination. The further exploration of HRT variability,
437 particularly its relationship with heart-rate variability, could help differentiate between
438 random fluctuations and inherent variability. In further investigations of HRT variability,
439 valuable information about the propagation of blood flow could be gained.

440

441 The study has limitations of different origins. One is the small number of subjects
442 included in the study. This was partly compensated by the repetitive acquisition and
443 will be further addressed by generating normative databases in a larger population in

444 the future. Future work will also expand the study populations to include subjects with
445 cardiovascular diseases to evaluate and validate the potential of the HRT as a
446 biomarker. Another factor is the synchronisation mechanism, which consists of a
447 calibration of the PC and ECG time series via NTP. In the future, mechanisms to use
448 the same clock for the ECG and OCT could be investigated. In this work, we were
449 limited by the used devices, which did not allow for a direct access of the clock of the
450 other instrument, potentially leading to a HRT biases between different acquisitions. A
451 further limitation is the time-consuming analysis procedure of single arteriole centres.
452 However, the 26'100 annotated vessel centres from this study could serve as the basis
453 for the development of automated landmark detection systems, alleviating the manual
454 burden.

455

456 Our study's main strength is that we developed a method with a widely used
457 commercially available OCT device. Second, the ECG device we used is based on an
458 open-source device, which would allow for an easy integration with different OCT
459 devices. Hence, this means that the method can be used and reproduced in other
460 settings, where time-resolved OCT acquisitions are feasible. Third, we propose a
461 quantitative method to assess the cardiovascular state. Similar to other pulse wave
462 velocity methods, we provide a specific method for the propagation from the heart to
463 the eye. Future studies will assess the validation and clinical usability of the HRT as a
464 biomarker for cardiovascular health.

465 **Conclusions**

466 In this study, we propose a method to analyse the propagation of blood flow from the
467 heart to the retina. We demonstrated the feasibility of ECG-coupled time-resolved
468 OCT acquisitions and the correlation between the cardiac cycle and retinal pulse
469 waves. The cross-correlation of the ECG and the blood flow profiles in retinal
470 arterioles revealed the propagation of the blood column within a cardiac cycle. By
471 analysing the lag between the two signals, the HRT can be calculated. The
472 investigation of blood flow propagation is an important field to better understand
473 vascular turbulences. The synchronised acquisition of ECG with dynamic OCT offers
474 a method to explore cardiovascular and ocular health interconnections. This study
475 establishes the foundation for utilising the HRT as a potential biomarker in evaluating
476 systemic and ocular vascular conditions.

477 References

- 478 1. Flammer, J. *et al.* The eye and the heart. *Eur Heart J* **34**, 1270–1278 (2013).
- 479 2. Chatterjee, S., Chattopadhyaya, S., Hope-Ross, M. & Lip, P. L. Hypertension and the eye:
480 changing perspectives. *Journal of Human Hypertension* **2002 16:10 16**, 667–675 (2002).
- 481 3. Farrah, T. E., Dhillon, B., Keane, P. A., Webb, D. J. & Dhaun, N. The eye, the kidney, and
482 cardiovascular disease: old concepts, better tools, and new horizons. *Kidney International* vol.
483 98 323–342 Preprint at <https://doi.org/10.1016/j.kint.2020.01.039> (2020).
- 484 4. Brown, G. C., Shah, H. G., Magargal, L. E. & Savino, P. J. Central Retinal Vein Obstruction
485 and Carotid Artery Disease. *Ophthalmology* **91**, 1627–1633 (1984).
- 486 5. Wong, T. Y. *et al.* Retinal Microvascular Abnormalities and their Relationship with
487 Hypertension, Cardiovascular Disease, and Mortality. *Surv Ophthalmol* **46**, 59–80 (2001).
- 488 6. Wong, T. Y. *et al.* Retinal microvascular abnormalities and incident stroke: The Atherosclerosis
489 Risk in Communities Study. *Lancet* **358**, 1134–1140 (2001).
- 490 7. Kewcharoen, J. *et al.* Prevalence of Atrial Fibrillation in Patients with Retinal Vessel Occlusion
491 and Its Association: A Systematic Review and Meta-Analysis. *Curr Eye Res* **44**, 1337–1344
492 (2019).
- 493 8. Martis, R. J., Acharya, U. R. & Adeli, H. Current methods in electrocardiogram
494 characterization. *Comput Biol Med* **48**, 133–149 (2014).
- 495 9. Huang, D. *et al.* Optical coherence tomography. *Science (1979)* **254**, 1178–1181 (1991).
- 496 10. Fujimoto, J. & Swanson, E. The development, commercialization, and impact of optical
497 coherence tomography. *Investigative Ophthalmology and Visual Science* vol. 57 OCT1–
498 OCT13 Preprint at <https://doi.org/10.1167/iovs.16-19963> (2016).
- 499 11. Valmaggia, P. *et al.* Time-Resolved Dynamic Optical Coherence Tomography for Retinal
500 Blood Flow Analysis. *Invest Ophthalmol Vis Sci* **65**, 9–9 (2024).
- 501 12. Spaide, R. F., Fujimoto, J. G., Waheed, N. K., Sadda, S. R. & Staurengi, G. Optical
502 coherence tomography angiography. *Prog Retin Eye Res* **64**, 1–55 (2018).
- 503 13. Ploner, S. B. *et al.* Toward quantitative optical coherence tomography angiography: Visualizing
504 blood flow speeds in ocular: Pathology using variable interscan time analysis. in *Retina* vol. 36
505 S118–S126 (NIH Public Access, 2016).
- 506 14. Hwang, Y. *et al.* Retinal blood flow speed quantification at the capillary level using temporal
507 autocorrelation fitting OCTA [Invited]. *Biomed Opt Express* **14**, 2658 (2023).
- 508 15. Dogan, M., Akdogan, M., Sabaner, C. & Gobeka, H. H. Morphological changes in
509 retinochoroidal microvasculature after caffeinated versus decaffeinated coffee consumption ☆.
510 *Photodiagnosis Photodyn Ther* **40**, 1572–1000 (2022).
- 511 16. Spaide, R. F. *et al.* Imaging the vitreous with a novel boosted optical coherence tomography
512 technique: Vitreous degeneration and cisterns. *Retina* **42**, 1433–1441 (2022).
- 513 17. Spaide, R. F., Valmaggia, P. & Maloca, P. M. IMAGING the VITREOUS with A NOVEL
514 BOOSTED OPTICAL COHERENCE TOMOGRAPHY TECHNIQUE: Posterior Vitreous
515 Detachment. *Retina* **42**, 1425–1432 (2022).
- 516 18. Thilagavathy, R. *et al.* Real-Time ECG Signal Feature Extraction and Classification using
517 Support Vector Machine. *2020 International Conference on Contemporary Computing and
518 Applications, IC3A 2020* 44–48 (2020) doi:10.1109/IC3A48958.2020.233266.

- 519 19. Ashwin K Whitchurch et al. HealthyPi v4 Arduino Library.
520 https://github.com/Protocentral/protocentral_healthypi4_arduino (2021).
- 521 20. Bernier, L. G., Dudle, G. & Schlunegger, C. METAS time & frequency metrology report. in
522 *Proceedings of the IEEE International Frequency Control Symposium and Exposition* vol. 2005
523 213–216 (Institute of Electrical and Electronics Engineers Inc., 2005).
- 524 21. Porr, B. & Howell, L. R-peak detector stress test with a new noisy ECG database reveals
525 significant performance differences amongst popular detectors. *bioRxiv* 722397 (2019)
526 doi:10.1101/722397.
- 527 22. Engelse, W. A. H. & Zeelenberg, C. A single scan algorithm for QRS-detection and feature
528 extraction. *Comput Cardiol* **6**, 37–42 (1979).
- 529 23. Thévenaz, P., Ruttimann, U. E. & Unser, M. A pyramid approach to subpixel registration based
530 on intensity. *IEEE Transactions on Image Processing* **7**, 27–41 (1998).
- 531 24. Lou, W. *et al.* Comparison of Two Spectral-domain Optical Coherence Tomography Scan
532 Modes for Measuring Retinal Vessel Diameter.
533 <https://doi.org/10.1080/02713683.2020.1862238> **46**, 1025–1030 (2021).
- 534 25. Yun, S. H., Tearney, G. J., de Boer, J. F. & Bouma, B. E. Motion artifacts in optical coherence
535 tomography with frequency-domain ranging. *Opt Express* **12**, 2977 (2004).
- 536 26. Fedorov, A. *et al.* 3D Slicer as an image computing platform for the Quantitative Imaging
537 Network. *Magn Reson Imaging* **30**, 1323–1341 (2012).
- 538 27. Wong, T. Y. & Mitchell, P. Hypertensive Retinopathy. <https://doi.org/10.1056/NEJMra032865>
539 **351**, 2310–2317 (2004).
- 540 28. Zhou, Y. *et al.* AutoMorph: Automated Retinal Vascular Morphology Quantification Via a Deep
541 Learning Pipeline. *Transl Vis Sci Technol* **11**, 12–12 (2022).
- 542 29. Wagner, S. K. *et al.* Insights into Systemic Disease through Retinal Imaging-Based Oculomics.
543 *Transl Vis Sci Technol* **9**, (2020).
- 544 30. Saruhan, Y., Bollinger, O. & Gugleta, K. Analysis of Retinal Vessel Pulsation with
545 Electrographic Gating - Pulsation Amplitude and the Influence of Hyperoxia. *Klin Monbl*
546 *Augenheilkd* **237**, 469–473 (2020).
- 547 31. Bollinger, O., Saruhan, Y. & Gugleta, K. Analysis of Retinal Vessel Pulsations with
548 Electrocardiographic Gating. *Klin Monbl Augenheilkd* **237**, 464–468 (2020).
- 549 32. Salvi, P. *et al.* Systolic time intervals assessed from analysis of the carotid pressure waveform.
550 *Physiol Meas* **39**, 084002 (2018).
- 551 33. Katamay, R., Fleischlin, C., Gugleta, K., Flammer, J. & Orgül, S. Volumetric blood flow
552 measurement in the ophthalmic artery using colour Doppler. *Klin Monbl Augenheilkd* **226**,
553 249–253 (2009).
- 554 34. Littlewood, R., Mollan, S. P., Pepper, I. M. & Hickman, S. J. The Utility of Fundus Fluorescein
555 Angiography in Neuro-Ophthalmology. *Neuro-Ophthalmology* vol. 43 217–234 Preprint at
556 <https://doi.org/10.1080/01658107.2019.1604764> (2019).
- 557 35. Rockey, J. H., Li, W. & Eccleston, J. F. Binding of fluorescein and carboxyfluorescein by
558 human serum proteins: Significance of kinetic and equilibrium parameters of association in
559 ocular fluorometric studies. *Exp Eye Res* **37**, 455–466 (1983).
- 560 36. Penniston, J. T. Fluorescence polarization measurement of binding of fluorescein to albumin.
561 *Exp Eye Res* **34**, 435–443 (1982).

- 562 37. Pour Ebrahim, M. *et al.* Blood Pressure Estimation Using On-body Continuous Wave Radar
563 and Photoplethysmogram in Various Posture and Exercise Conditions. *Sci Rep* **9**, (2019).
- 564 38. Vischer, A. S. & Burkard, T. Principles of blood pressure measurement – current techniques,
565 office vs ambulatory blood pressure measurement. in *Advances in Experimental Medicine and*
566 *Biology* vol. 956 85–96 (Springer New York LLC, 2017).
- 567 39. Muehlsteff, J., Aubert, X. L. & Schuett, M. Cuffless estimation of systolic blood pressure for
568 short effort bicycle tests: The prominent role of the pre-ejection period. in *Annual International*
569 *Conference of the IEEE Engineering in Medicine and Biology - Proceedings* 5088–5092
570 (2006). doi:10.1109/IEMBS.2006.260275.
- 571 40. Block, R. C. *et al.* Conventional pulse transit times as markers of blood pressure changes in
572 humans. *Sci Rep* **10**, 1–9 (2020).
- 573 41. Ding, X. R., Zhang, Y. T., Liu, J., Dai, W. X. & Tsang, H. K. Continuous Cuffless Blood
574 Pressure Estimation Using Pulse Transit Time and Photoplethysmogram Intensity Ratio. *IEEE*
575 *Trans Biomed Eng* **63**, 964–972 (2016).
- 576 42. Ding, X. & Zhang, Y. T. Pulse transit time technique for cuffless unobtrusive blood pressure
577 measurement: from theory to algorithm. *Biomedical Engineering Letters* vol. 9 37–52 Preprint
578 at <https://doi.org/10.1007/s13534-019-00096-x> (2019).
- 579 43. Huttunen, J. M. J., Kärkkäinen, L. & Lindholm, H. Pulse transit time estimation of aortic pulse
580 wave velocity and blood pressure using machine learning and simulated training data. *PLoS*
581 *Comput Biol* **15**, (2019).
- 582 44. Chao, H., Wang, Q., Avolio, A. & Zuo, J. COMPARISON OF INFLUENCE OF OFFICE PULSE
583 WAVE VELOCITY AND 24-HOUR AMBULATORY RECORDING OF AORTIC PULSE WAVE
584 VELOCITY ON TARGET DAMAGE IN HYPERTENSION. *J Hypertens* **41**, e266 (2023).
- 585 45. Jae, S. Y., Heffernan, K. S., Kurl, S., Kunutsor, S. K. & Laukkanen, J. A. Association between
586 estimated pulse wave velocity and the risk of stroke in middle-aged men. *International Journal*
587 *of Stroke* **16**, 551–555 (2021).
- 588 46. Kim, H. G., Cheon, E. J., Bai, D. S., Lee, Y. H. & Koo, B. H. Stress and Heart Rate Variability:
589 A Meta-Analysis and Review of the Literature. *Psychiatry Investig* **15**, 235 (2018).
- 590
- 591

592 **Acknowledgments**

593 This study received funding via personal grants to PV from the Swiss National Science
594 Foundation (Grant 323530_199395), AlumniMedizin Basel and the Janggen-Pöhn
595 Foundation. In addition, the researchers would like to thank all the participants who
596 volunteered for this study.

597

598 **Author contributions**

599 PV: Conceptualisation, methodology, software, validation, formal analysis,
600 investigation, resources, data acquisition, data processing, writing (original draft
601 preparation), writing (review and editing), visualisation and project administration.

602 JW: Methodology, software, validation, formal analysis, investigation, writing (review
603 and editing).

604 FB: Methodology, software, validation, formal analysis, investigation, writing (review
605 and editing).

606 HPNS: Methodology, validation, investigation, resources, writing (review and editing)
607 and project administration.

608 PCC: Conceptualisation, methodology, software, validation, formal analysis,
609 investigation, resources, data processing, writing (original draft preparation), writing
610 (review and editing) and project administration.

611 PMM: Conceptualisation, methodology, validation, formal analysis, investigation,
612 resources, data processing, writing (original draft preparation), writing (review and
613 editing), visualisation and project administration.

614 **Ethics declarations**

615 PV received speaker fees from Heidelberg Engineering GmbH and Bayer.

616 HPNS is supported by the Swiss National Science Foundation (Project funding:
617 “Developing novel outcomes for clinical trials in Stargardt disease using
618 structure/function relationship and deep learning” #310030_201165, and National
619 Center of Competence in Research Molecular Systems Engineering: “NCCR MSE:
620 Molecular Systems Engineering (phase II)” #51NF40-182895, the Wellcome Trust
621 (PINNACLE study), and the Foundation Fighting Blindness Clinical Research
622 Institute (ProgStar study). Dr. Scholl is member of the Scientific Advisory Board of:
623 Boehringer Ingelheim Pharma GmbH & Co; Droia NV; Eluminex Biosciences;
624 Janssen Research & Development, LLC (Johnson & Johnson); Okuvision GmbH;
625 ReVision Therapeutics Inc.; and Saliogen Therapeutics Inc. Dr. Scholl is a consultant
626 of: Alnylam Pharmaceuticals Inc.; Gerson Lehrman Group Inc.; Guidepoint Global,
627 LLC; and Tenpoint Therapeutics. Dr. Scholl is member of the Data Monitoring and
628 Safety Board/Committee of Belite Bio (DRAGON trial, NCT05244304; LBS-008-
629 CT02, NCT05266014), F. Hoffmann-La Roche Ltd (VELODROME trial,
630 NCT04657289; DIAGRID trial, NCT05126966; HUTONG trial), ViGeneron (protocol
631 number VG901-2021-A) and member of the Steering Committee of Novo Nordisk
632 (FOCUS trial; NCT03811561).

633 PMM is a consultant of Roche and holds intellectual properties for machine learning
634 at MIMO AG and VisionAI, Switzerland.

635 The other authors declare no conflict. Funding organisations had no influence on the
636 design, performance or evaluation of the current study.

637 **Data availability**

638 The data presented in this paper are not publicly available due to data protection
639 regulations. Interested parties may request access to the data from the
640 corresponding author (PV) upon reasonable request and approval from the
641 concerned institutional review boards.

642

643 **Supplementary Material**

644 **Supplementary Video 1**

645 Electrocardiogram-coupled time-resolved dynamic optical coherence tomography at
646 the optic nerve head. The pulsatile intensity changes at the centre of the arterioles
647 are due to fringe washout.

648 **Supplementary Video 2**

649 Electrocardiogram-coupled time-resolved dynamic optical coherence tomography of
650 an arteriole with synchronised velocity profile and electrocardiogram trace at the
651 optic nerve head. The ocular blood flow pulsations match in frequency with the heart
652 beat.

653 **Supplementary Video 3**

654 Electrocardiogram-coupled time-resolved dynamic optical coherence tomography of
655 three arterioles with synchronised velocity profiles and electrocardiogram trace at the
656 optic nerve head. The ocular blood flow pulsations match in frequency. The arrival
657 time can be calculated and is denoted as the heart-retina time.